Corcept Therapeutics Inc. diskutieren
Corcept Therapeutics Inc.
WKN: 529882 / Symbol: CORT / Name: Corcept / Aktie / Pharmazeutika / Small Cap /
42,21 €
7,30 %
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $33.00 to $32.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $32.00 to $34.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock, up previously from $29.00.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target lowered by analysts at HC Wainwright from $34.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Truist Financial Co. from $36.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Truist Financial Co. from $42.00 to $44.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $38.00 to $40.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $65.00 price target on the stock, up previously from $44.00.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $65.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $35.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $40.00 to $45.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $35.00 to $38.00. They now have an "overweight" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $38.00 to $67.00. They now have an "overweight" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Truist Financial Co. from $65.00 to $76.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Neueste Beiträge
DA_Davidson in i3 Verticals diskutieren